Braizon Therapeutics, Inc. This revolutionary technology, developed through the collaborative research efforts of Professor Kazunori Kataoka in the Department of Engineering and Medicine at the University of Tokyo and Professor Takenori Yokota at the Graduate School of Medical and Dental Sciences at Tokyo Medical and Dental University, enables the delivery of drugs into the brain. Based on this technology, Braizon Therapeutics has created the drug delivery system platform called Brain Access®.

This platform can be utilized through partnerships with pharmaceutical companies, biotech firms, and academic institutions. Additionally, leveraging the power of this foundational technology and the expertise of Team Braizon, we are committed to creating new treatments for CNS diseases that have not received sufficient attention by building a pipeline focused on medical needs. Furthermore, we are excited to announce that we are currently developing the Transferrin Receptor (TfR) pathway in addition to GLUT1 as a delivery pathway for Brain Access® since late 2020.

This will accelerate the business realization of our platform. For more information, please visit our website. At Braizon Therapeutics, we are driven by a passionate team of directors who possess extensive experience in the practical application of newly invented technologies with significant and beneficial social impact.

Our leadership team consists of individuals with exceptional abilities and diverse experiences in leadership, finance, business partnerships, drug development, and clinical translation. Supported by their collective capabilities and expertise, Braizon Therapeutics is poised to become a strong pharmaceutical company focused on developing potent therapeutics for CNS disorders. As a company rooted in science and supported by venture capital, Braizon Therapeutics operates with the goal of enabling superior treatment methods for CNS diseases by utilizing our innovative drug delivery system platform.

Brain Access® offers the highest level of drug delivery, excellent target selectivity, and versatile applicability for the development of new life-saving treatment methods in the CNS field. By licensing this platform to pharmaceutical industry partners and dedicating our efforts to internal development projects, we strive to create shareholder value. Join us in our mission! We are currently seeking like-minded individuals to join our team as we pursue the social implementation of our business, selected as part of J-startUp and Nikkei NEXT Unicorn.

If you are up for the challenge, please visit our website for more information. Copyright 2023 Braizon Therapeutics, Inc. All rights reserved